| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 12/11/2001 | CA2066053C Recombinant retroviruses delivering vector constructs to target cells |
| 12/08/2001 | CA2349776A1 Novel crystalline forms of (3s-trans)-2-¬3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2h-1-benzopyran-7-yl|-4-(trifluoromethyl)-benzoic acid |
| 12/06/2001 | WO2001092581A2 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 12/06/2001 | WO2001092547A2 Modified bovine adenovirus having altered tropism |
| 12/06/2001 | WO2001092532A1 Cloning and sequencing of dac g5 allergen of dactylis glomerata pollen, preparation and use thereof |
| 12/06/2001 | WO2001092531A1 Cloning and sequencing the dac g1 allergen of dactylis glomerata pollen, preparation and use thereof |
| 12/06/2001 | WO2001092530A1 Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide |
| 12/06/2001 | WO2001092527A2 Regulators of apoptosis |
| 12/06/2001 | WO2001092513A1 METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi |
| 12/06/2001 | WO2001092491A2 Mammalian protein phosphatases identified by in-silico analysis |
| 12/06/2001 | WO2001092485A1 DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE |
| 12/06/2001 | WO2001092474A1 Alpha (2) macroglobulin receptors as a heat shock protein receptor and uses thereof |
| 12/06/2001 | WO2001092337A2 Soluble ctla4 mutant molecules and uses thereof |
| 12/06/2001 | WO2001092304A2 Transporters and ion channels |
| 12/06/2001 | WO2001092294A2 Therapeutic anti-melanoma compounds |
| 12/06/2001 | WO2001092267A2 Dihydropyridine compounds for the inhibition of calcium-influx |
| 12/06/2001 | WO2001092256A1 2,7-naphthyridine derivatives |
| 12/06/2001 | WO2001092253A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 12/06/2001 | WO2001092233A1 3-substituted isoquinolin-1-yl derivatives |
| 12/06/2001 | WO2001092229A1 TNF-α PRODUCTION INHIBITORS |
| 12/06/2001 | WO2001092227A1 Chemical compounds |
| 12/06/2001 | WO2001092224A1 Indole derivatives with vascular damaging activity |
| 12/06/2001 | WO2001092221A1 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds |
| 12/06/2001 | WO2001092220A1 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof |
| 12/06/2001 | WO2001092218A2 Polyamine analogues as therapeutic and diagnostic agents |
| 12/06/2001 | WO2001092202A1 Il-8 receptor antagonists |
| 12/06/2001 | WO2001091803A2 Methods and compounds for controlled release of recombinant parvovirus vectors |
| 12/06/2001 | WO2001091799A2 Medicament for the treatment of immune reactions in the eye |
| 12/06/2001 | WO2001091793A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 12/06/2001 | WO2001091792A2 Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network |
| 12/06/2001 | WO2001091791A2 Immune-stimulating bacterial cell wall extracts |
| 12/06/2001 | WO2001091789A2 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
| 12/06/2001 | WO2001091787A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | WO2001091780A1 Neuroprotective peptides |
| 12/06/2001 | WO2001091754A1 Protein kinase inhibitors |
| 12/06/2001 | WO2001091729A1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
| 12/06/2001 | WO2001091719A1 Nasal ointment based on white petroleum jelly |
| 12/06/2001 | WO2001091698A2 Genetically-engineered mhc molecules |
| 12/06/2001 | WO2001053351A3 Apoptin bindendes protein |
| 12/06/2001 | WO2001051644A3 ANTI-CD3 SINGLE-CHAIN ANTIBODIES HAVING HUMAN Cν3 AND Cν4 DOMAINS |
| 12/06/2001 | WO2001049717A3 Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or t cell subset activity by modulation of xbp-1 activity |
| 12/06/2001 | WO2001049673A3 Compounds and methods for modulation of estrogen receptors |
| 12/06/2001 | WO2001046392A3 Homologues of human heparanase and splice variants thereof |
| 12/06/2001 | WO2001040229A3 Method for producing epinastine hydrochloride in the high-melting crystal modification |
| 12/06/2001 | WO2001034138B1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 12/06/2001 | WO2001030854A3 Antibody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin |
| 12/06/2001 | WO2001022977A3 Echinacea supplement and method of manufacture |
| 12/06/2001 | WO2001019800A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 12/06/2001 | WO2001018042A3 Apoptosis proteins |
| 12/06/2001 | WO2001017999A3 Amino-triazolopyridine derivatives |
| 12/06/2001 | WO2001016345A3 Sequence-specific dna recombination in eukaryotic cells |
| 12/06/2001 | WO2001012775A8 25 human secreted proteins |
| 12/06/2001 | WO2001012662A3 Membrane associated proteins |
| 12/06/2001 | WO2000077018A3 Purine derivatives |
| 12/06/2001 | WO2000072868A3 Peptides for therapeutic use |
| 12/06/2001 | WO2000061750A3 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS |
| 12/06/2001 | US20010049446 C-C9-Heteroaryl, linked via C or N, substituted or unsubstitued by 1,3-substituents, substituted benzoylguanidine derivatives useful for treating ischemia, cardiac infarct, angina pectoris, and storke etc. |
| 12/06/2001 | US20010049377 Glucocortiocoid-selective antiinflammatory agents |
| 12/06/2001 | US20010049367 Cyclic and bicyclic diamino histamine-3 receptor antagonists |
| 12/06/2001 | US20010049353 Stimulating secretion of pancreatic juices |
| 12/06/2001 | US20010049142 A rapid, simple-to-use method to differentiate nondividing cells by fusing two different cells and then purifying them without antibiotic or metabolic selection; kits with two nontoxic dyes and instructions; antitumor agents |
| 12/06/2001 | US20010049137 DNA fragments derived from the genomic DNA of HPV-33, including recombinant vectors, which cells are replicated in host cells and expressed as immunogenic proteins; diagnosis of tumors; antibodies to detect viral infections |
| 12/06/2001 | US20010049122 For reducing inflammation, for treating an autoimmune disease, for enhancing transplantation of tissue grafts, increasing antitumor immunity, and inhibiting viral and parasitic infections |
| 12/06/2001 | US20010049106 ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain thrombospondin domain (TS); treating diabetes, arthritis, cancer, solid tumors, autoimmune diseases |
| 12/06/2001 | US20010048948 Intestine health; immunology; mixture containing whey |
| 12/06/2001 | DE10026699A1 Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage Formulation of heparin, glycosaminoglycan or Heparinoidbasis and use of the formulation and the formulation base |
| 12/06/2001 | DE10025920A1 Verfahren und Mittel zur Behandlung von Immunreaktionen am Auge Method and agent for the treatment of immune responses in the eye |
| 12/06/2001 | DE10025464A1 Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen Combined use of enzyme inhibitors for the therapy of autoimmune diseases, transplantation and tumor diseases as well as combinations of enzyme inhibitors pharmaceutical preparations comprising |
| 12/06/2001 | CA2736344A1 Tnf-.alpha. production inhibitors |
| 12/06/2001 | CA2413188A1 Petrolatum-based nose ointment |
| 12/06/2001 | CA2411404A1 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 12/06/2001 | CA2411323A1 Il-8 receptor antagonists |
| 12/06/2001 | CA2411040A1 Therapeutic anti-melanoma compounds |
| 12/06/2001 | CA2410947A1 Methods for mediating gene suppresion by using factors that enhance rnai |
| 12/06/2001 | CA2410935A1 Novel polyamine analogues as therapeutic and diagnostic agents |
| 12/06/2001 | CA2410903A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | CA2410736A1 Alpha (2) macroglobulin receptors as a heat shock protein receptor and uses thereof |
| 12/06/2001 | CA2410734A1 Dnas encoding mammalian histamine receptor of the h4 subtype |
| 12/06/2001 | CA2410665A1 Modified bovine adenovirus having altered tropism |
| 12/06/2001 | CA2410655A1 Dihydropyridine compounds for the inhibition of calcium-influx |
| 12/06/2001 | CA2410640A1 3-substituted isoquinolin-1-yl derivatives |
| 12/06/2001 | CA2410453A1 Neuroprotective peptides |
| 12/06/2001 | CA2410087A1 Mammalian protein phosphatases identified by in-silico analysis |
| 12/06/2001 | CA2410084A1 Transporters and ion channels |
| 12/06/2001 | CA2409932A1 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
| 12/06/2001 | CA2409617A1 2,7-naphthyridine derivatives |
| 12/06/2001 | CA2409597A1 Protein kinase inhibitors |
| 12/06/2001 | CA2409311A1 Regulators of apoptosis |
| 12/06/2001 | CA2406979A1 Indole derivatives with vascular damaging activity |
| 12/06/2001 | CA2383432A1 Therapeutic immune condition compositions and methods |
| 12/05/2001 | EP1160319A2 Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (TGF-beta) |
| 12/05/2001 | EP1160255A1 Monovalent antibody fragments |
| 12/05/2001 | EP1160254A1 Human vanilloid receptor-like proteins |
| 12/05/2001 | EP1160248A1 N-(Isoxazol-5-yl)-sulfonamide derivatives and their use as endothelin antagonists |
| 12/05/2001 | EP1159962A1 Liposome preparations |
| 12/05/2001 | EP1159958A1 Vaseline-based nasal ointment |
| 12/05/2001 | EP1159457A1 T cell receptor vbeta beta-jbeta) sequence and methods for its detection |
| 12/05/2001 | EP1159418A2 Muc-1 antagonists and methods of treating immune disorders |
| 12/05/2001 | EP1159417A2 Polynucleotides and proteins encoded thereby |
| 12/05/2001 | EP1159300A2 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |